Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Texas: - Houston Methodist San Jacinto Hospital — Baytown, Texas
- MD Anderson in The Woodlands — Conroe, Texas
- Houston Methodist Cypress Hospital — Cypress, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Texas: - University of Texas Southwestern Medical Center - Simmons Cancer Center — Dallas, Texas
- University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital — Dallas, Texas
- University of Texas Southwestern Medical Center-Zale Lipshy University Hospital — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Texas: - Investigative Site US067 — Dallas, Texas
- Investigative Site US062 — Denison, Texas
- Investigative Site US011 — Houston, Texas
- Investigative Site US018 — Houston, Texas
- Investigative Site US080 — San Antonio, Texas
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Texas: - Baylor Scott and White Research Institute (Adults only) — Dallas, Texas
- University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only) — Dallas, Texas
- MD Anderson Cancer Center (Pediatrics and Adult) — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Texas: - Exelixis Clinical Site #10 — Dallas, Texas
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Texas: - Research Facility — Houston, Texas
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in Texas: - UT Southwestern Medical Center at Dallas — Dallas, Texas
- Houston Methodist Office of Graduate - Houston Methodist Neal Cancer Center at Texas Medical Center — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
- Texas Oncology Gulf Coast — Webster, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Sites in Texas: - SCRI - Texas Oncology Dallas — Dallas, Texas
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in Texas: - Investigative Site — Houston, Texas
Phase 3 Recruiting Academic/Other
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06593431
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pan…
Sponsor: Oncotelic Inc.
NCT ID: NCT06079346
Sites in Texas: - Baylor College of Medicine — Houston, Texas
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Texas: - Ohio State University Telemedicine — Amarillo, Texas
- Ohio State University-Telemedicine — Austin, Texas
- Ohio State University-Telemedicine — Dallas, Texas
- Ohio State University Telemedicine — Fort Stockton, Texas
- Ohio State University-Telemedicine — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
- Oncology Consultants — Houston, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Texas: - University of Texas at Austin — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Next Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Texas: - University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Dallas — Irving, Texas
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic …
Sponsor: Corcept Therapeutics
NCT ID: NCT07259317
Sites in Texas: - Site 01 — San Antonio, Texas
Phase 2 Recruiting Industry
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04924075
Sites in Texas: - University of Texas MD Anderson Cancer Center ( Site 0112) — Houston, Texas